Your browser doesn't support javascript.
loading
An OpenData portal to share COVID-19 drug repurposing data in real time
Kyle R. Brimacombe; Tongan Zhao; Richard T Eastman; Xin Hu; Ke Wang; Mark Backus; Bolormaa Baljinnyam; Catherine Z. Chen; Lu Chen; Tara Eicher; Marc Ferrer; Ying Fu; Kirill Gorshkov; Hui Guo; Quinlin M Hanson; Zina Itkin; Stephen C Kales; Carleen Klumpp-Thomas; Emily M Lee; Sam Michael; Tim Mierzwa; Andrew Patt; Manisha Pradhan; Alex Renn; Paul Shinn; Jonathan H Shrimp; Amit Viraktamath; Kelli M Wilson; Miao Xu; Alexey V Zakharov; Wei Zhu; Wei Zheng; Anton Simeonov; Ewy A Mathé; Donald C Lo; Matthew D Hall; Min Shen.
Afiliación
  • Kyle R. Brimacombe; National Center for Advancing Translational Sciences, NIH
  • Tongan Zhao; National Center for Advancing Translational Sciences, NIH
  • Richard T Eastman; National Center for Advancing Translational Sciences, NIH
  • Xin Hu; National Center for Advancing Translational Sciences, NIH
  • Ke Wang; National Center for Advancing Translational Sciences, NIH
  • Mark Backus; National Center for Advancing Translational Sciences, NIH
  • Bolormaa Baljinnyam; National Center for Advancing Translational Sciences, NIH
  • Catherine Z. Chen; National Center for Advancing Translational Sciences, NIH
  • Lu Chen; National Center for Advancing Translational Sciences, NIH
  • Tara Eicher; National Center for Advancing Translational Sciences, NIH
  • Marc Ferrer; National Center for Advancing Translational Sciences, NIH
  • Ying Fu; National Center for Advancing Translational Sciences, NIH
  • Kirill Gorshkov; National Center for Advancing Translational Sciences, NIH
  • Hui Guo; National Center for Advancing Translational Sciences, NIH
  • Quinlin M Hanson; National Center for Advancing Translational Sciences, NIH
  • Zina Itkin; National Center for Advancing Translational Sciences, NIH
  • Stephen C Kales; National Center for Advancing Translational Sciences, NIH
  • Carleen Klumpp-Thomas; National Center for Advancing Translational Sciences, NIH
  • Emily M Lee; National Center for Advancing Translational Sciences, NIH
  • Sam Michael; National Center for Advancing Translational Sciences, NIH
  • Tim Mierzwa; National Center for Advancing Translational Sciences, NIH
  • Andrew Patt; National Center for Advancing Translational Sciences, NIH
  • Manisha Pradhan; National Center for Advancing Translational Sciences, NIH
  • Alex Renn; National Center for Advancing Translational Sciences, NIH
  • Paul Shinn; National Center for Advancing Translational Sciences, NIH
  • Jonathan H Shrimp; National Center for Advancing Translational Sciences, NIH
  • Amit Viraktamath; National Center for Advancing Translational Sciences, NIH
  • Kelli M Wilson; National Center for Advancing Translational Sciences, NIH
  • Miao Xu; National Center for Advancing Translational Sciences, NIH
  • Alexey V Zakharov; National Center for Advancing Translational Sciences, NIH
  • Wei Zhu; National Center for Advancing Translational Sciences, NIH
  • Wei Zheng; National Center for Advancing Translational Sciences, NIH
  • Anton Simeonov; National Center for Advancing Translational Sciences, NIH
  • Ewy A Mathé; National Center for Advancing Translational Sciences, NIH
  • Donald C Lo; National Center for Advancing Translational Sciences, NIH
  • Matthew D Hall; National Center for Advancing Translational Sciences, NIH
  • Min Shen; National Center for Advancing Translational Sciences, NIH
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-135046
ABSTRACT
The National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign - named OpenData - with the goal of making data across a range of SARS-CoV-2 related assays available in real-time. The assays developed cover a wide spectrum of the SARS-CoV-2 life cycle, including both viral and human (host) targets. In total, over 10,000 compounds are being tested in full concentration-response ranges from across multiple annotated small molecule libraries, including approved drug, repurposing candidates and experimental therapeutics designed to modulate a wide range of cellular targets. The goal is to support research scientists, clinical investigators and public health officials through open data sharing and analysis tools to expedite the development of SARS-CoV-2 interventions, and to prioritize promising compounds and repurposed drugs for further development in treating COVID-19.
Licencia
cc_by_nc_nd
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint